Dyclone
(Dyclonine hydrochloride mucilage)Preclinical
AstraZenecaDyclone is one of 7 small molecule programs targeting Gastrointestinal. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Gastrointestinal
#DrugCompanyPhaseTrials
1Movantik
AAveritas Pharma, Inc.
Phase 3
Cytalux
OOn Target Laboratories, LLC
Phase 3
Octreotide
Johnson & JohnsonPreclinical
Dyclone
AstraZenecaPreclinical
Mosapride Citrate
IlDong Pharmaceutical Co LtdPreclinical
Buscopan
Boehringer IngelheimPreclinical
Dachengqi Decoction
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastrointestinal1 trial
Dyclonine Hydrochloride Mucilage Versus Tetracaine Hydrochloride Jelly for Local Anesthesia in Unsedated Gastroscopy: A Non-inferiority Randomized Controlled Trial
Not yet recruiting·GGeneral Hospital of Shenyang Military Region·Preclinical·NCT07691346·208 enrolled
Regulatory
FDA Approval Timeline[4]
Dec 31, 1981
DYCLONE
NDA NDA009925
Sources
References
- [1]
- [2]
- [3]
- [4]
- [5]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company